Cargando…

MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice

Group 3 medulloblastoma is one of the most aggressive types of childhood brain tumors. Roughly 30% of cases carry genetic alterations in MYC, SMARCA4, or both genes combined. While overexpression of MYC has previously been shown to drive medulloblastoma formation in mice, the functional significance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Göbel, Carolin, Godbole, Shweta, Schoof, Melanie, Holdhof, Dörthe, Kresbach, Catena, Loose, Carolin, Neumann, Julia, Schüller, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621315/ https://www.ncbi.nlm.nih.gov/pubmed/37919824 http://dx.doi.org/10.1186/s40478-023-01654-2

Ejemplares similares

MEDB-11. MYC overexpression and SMARCA4 loss in cerebellar granule cell precursors cooperate to drive medulloblastoma formation in mice
por: Göbel, Carolin, et al.
Publicado: (2022)

MEDB-12. Severe developmental abnormalities and proliferative cerebellar lesions induced by combined activity of Wnt signalling and loss of SMARCA4
por: Göbel, Carolin, et al.
Publicado: (2022)

Simultaneous Brg1 Knockout and MYCN Overexpression in Cerebellar Granule Neuron Precursors Is Insufficient to Drive Tumor Formation but Temporarily Enhances their Proliferation and Delays their Migration
por: Holdhof, Dörthe, et al.
Publicado: (2021)

Generation of new transgenic SMARCA4‐deficient mouse models results in neuromuscular weakness and paralysis of limbs
por: Neyazi, Sina, et al.
Publicado: (2022)

HGG-15. Generation of a novel mouse model for brain tumors of the DNA methylation class “GBM MYCN”
por: Schoof, Melanie, et al.
Publicado: (2022)

The tumor suppressor CREBBP and the oncogene MYCN cooperate to induce malignant brain tumors in mice
por: Schoof, Melanie, et al.
Publicado: (2023)

MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma
por: Kresbach, Catena, et al.
Publicado: (2022)

BIOL-10. MOUSE MODELING OF PEDIATRIC MYCN GLIOMA REVEALS INTRATUMORAL HETEROGENEITY INCLUDING NEURONAL AND OLIGODENDROGLIAL LINEAGE SIGNATURES
por: Schoof, Melanie, et al.
Publicado: (2023)

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
por: Schoof, Melanie, et al.
Publicado: (2023)

Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome
por: Schoof, Melanie, et al.
Publicado: (2021)

Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond
por: Kresbach, Catena, et al.
Publicado: (2022)

Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors
por: Graf, Monika, et al.
Publicado: (2022)

Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma
por: Diaz, Roberto Jose, et al.
Publicado: (2014)

BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA
por: Llaguno, Sheila Alcantara, et al.
Publicado: (2023)

Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases
por: Holdhof, Dörthe, et al.
Publicado: (2020)

KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice
por: Sin, Sang-Hoon, et al.
Publicado: (2015)

Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling
por: Kresbach, Catena, et al.
Publicado: (2021)

CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma
por: Dahlin, Anna M., et al.
Publicado: (2015)

MEDB-67. Subgroup specific analysis of cellular metabolism in medulloblastoma
por: Funke, Viktoria, et al.
Publicado: (2022)

N-myc gene expression and oncoprotein characterisation in medulloblastoma.
por: Garson, J. A., et al.
Publicado: (1989)

Mouse medulloblastoma driven by CRISPR activation of cellular Myc
por: Vo, BaoHan T., et al.
Publicado: (2018)

OMIC-03. TRANSLATIONAL CONTROL IN MYC AND MYCN MEDULLOBLASTOMA
por: Schmidt, Christin, et al.
Publicado: (2021)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

A Carboxy-terminal Smarcb1 Point Mutation Induces Hydrocephalus Formation and Affects AP-1 and Neuronal Signalling Pathways in Mice
por: Brugmans, Aliska K., et al.
Publicado: (2023)

Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas
por: Urer, Halide Nur, et al.
Publicado: (2023)

MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities
por: Sequera, Celia, et al.
Publicado: (2022)

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
por: Borgenvik, Anna, et al.
Publicado: (2022)

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients
por: von Bueren, André O, et al.
Publicado: (2011)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS
por: Xu, Zhenhua, et al.
Publicado: (2021)

hGFAP-mediated GLI2 overexpression leads to early death and severe cerebellar malformations with rare tumor formation
por: Niesen, Judith, et al.
Publicado: (2023)

MDB-19. MULTIOMIC PROFILING OF MEDULLOBLASTOMA REVEALS SUBTYPE-SPECIFIC TARGETABLE ALTERATIONS AT THE PROTEOME AND N-GLYCAN LEVEL
por: Godbole, Shweta, et al.
Publicado: (2023)

A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma
por: Wang, Dong, et al.
Publicado: (2021)

The B Cell Antigen Receptor and Overexpression of MYC Can Cooperate in the Genesis of B Cell Lymphomas
por: Refaeli, Yosef, et al.
Publicado: (2008)

High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer
por: Guerrero-Martínez, Jose A., et al.
Publicado: (2018)

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
por: Cantley, Jennifer, et al.
Publicado: (2022)

ETMR-05. Single-cell transcriptomics of ETMR reveals developmental cellular programs and tumor-pericyte communications in the microenvironment
por: de Faria, Flavia W, et al.
Publicado: (2022)

Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism
por: Mohapatra, Bhopal C., et al.
Publicado: (2022)

Overexpressed TP73 induces apoptosis in medulloblastoma
por: Castellino, Robert C, et al.
Publicado: (2007)

MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
por: Bolin, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u8g5at6hc1dd54dq6c9hgq1om4